Cytokinetics, Incorporated

NASDAQ-GS: CYTK

.USD

-0.37 (0.55%)↓ today

Price at Apr 14, 4:00:01 PM EDT • Market Closed

Is it expensive?

Trailing P/E Ratio

Explainer

Trailing P/E shows what you are paying for each dollar of last year's earnings. It answers: "How expensive is this stock relative to its past year's profits?"

-10.20

Forward P/E Ratio

Explainer

Forward P/E shows what you are paying for each dollar of next year's projected earnings. It answers: "How expensive is this stock relative to its expected future profits?"

-13.42

PEG Ratio

Explainer

PEG Ratio measures if a stock is expensive relative to its growth rate. It answers: "Am I paying a fair price for growth?"

-0.54

Enterprise Value to EBITDA

-14.57

Price-to-Sales (TTM)

Explainer

Price-to-Sales (TTM) shows what you pay for each dollar of the company's revenue. It answers: "How expensive is this stock relative to sales?"

93.34

Price-to-Book (MRQ)

-12.38

Book Value per Share (MRQ)

-5.37

Market Cap

Explainer

Market Cap calculates a company's market value. It answers: "How big is this company and what size risk am I taking?"

8.22B

Enterprise Value

8.77B

Is it profitable?

Net Profit Margin (TTM)

Explainer

Net Profit Margin (TTM) shows what percentage of revenue remains after all costs. It answers: "How much does the company keep as a final profit?"

Profit Margin: The key to measuring true business profitability

-372.55%

Gross Profit Margin

Explainer

Gross Profit Margin shows what percentage of revenue remains after direct costs. It answers: "How much does the company keep before operating costs?"

Profit Margin: The key to measuring true business profitability

-487.99%

Diluted EPS (TTM)

Explainer

Diluted EPS (TTM) shows the profit per share over the last 12 months. It answers: "How profitable is each share I buy?"

Earnings per Share (EPS): The Key Metric That Beats Headline Profits

-6.54

Return on Equity (TTM)

119.00%

Revenue (TTM)

88.04M

Is it growing?

Revenue Growth (MRQ)

4.90%

Earnings Growth (YOY)

4.89%

Is it risky?

Beta

0.48

Debt to Equity (MRQ)

-2.18

Current Ratio (MRQ)

4.53

Total Debt (MRQ)

1.44B

Who owns it?

Institutional Ownership

115.43%

Insider Ownership

1.13%

Short Interest

16.44%

Shares Outstanding

122.94M

Shares Float

122.30M

Does it pay?

Forward Dividend Yield

0.00%

Payout Ratio

0.00%

Ex. Dividend Date

Dividend Date

How much cash?

Total Cash (MRQ)

882.22M

Operating Cash Flow (TTM)

-510.01M

Levered Free Cash Flow (TTM)

-379.62M

Total Cash per Share (MRQ)

7.16

Indicators

Founder-operated companies generally perform better.

Founders

James Sabry, James Spudich, Ronald Vale, Lawrence S.B. Goldstein

CEO

Robert I. Blum

Biotechnology

Operating Cash Flow

-510.01M

÷0

Net Income

-784.96M

Mixed Signal

0.65

Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.

Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.

Indicators

Founder-operated companies generally perform better.

Founders

James Sabry, James Spudich, Ronald Vale, Lawrence S.B. Goldstein

CEO

Robert I. Blum

Biotechnology

Operating Cash Flow

-510.01M

÷0

Net Income

-784.96M

Mixed Signal

0.65

Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.

Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.

Is it expensive?

Trailing P/E Ratio

Explainer

Trailing P/E shows what you are paying for each dollar of last year's earnings. It answers: "How expensive is this stock relative to its past year's profits?"

-10.20

Forward P/E Ratio

Explainer

Forward P/E shows what you are paying for each dollar of next year's projected earnings. It answers: "How expensive is this stock relative to its expected future profits?"

-13.42

PEG Ratio

Explainer

PEG Ratio measures if a stock is expensive relative to its growth rate. It answers: "Am I paying a fair price for growth?"

-0.54

Enterprise Value to EBITDA

-14.57

Price-to-Sales (TTM)

Explainer

Price-to-Sales (TTM) shows what you pay for each dollar of the company's revenue. It answers: "How expensive is this stock relative to sales?"

93.34

Price-to-Book (MRQ)

-12.38

Book Value per Share (MRQ)

-5.37

Market Cap

Explainer

Market Cap calculates a company's market value. It answers: "How big is this company and what size risk am I taking?"

8.22B

Enterprise Value

8.77B

Is it profitable?

Net Profit Margin (TTM)

Explainer

Net Profit Margin (TTM) shows what percentage of revenue remains after all costs. It answers: "How much does the company keep as a final profit?"

Profit Margin: The key to measuring true business profitability

-372.55%

Gross Profit Margin

Explainer

Gross Profit Margin shows what percentage of revenue remains after direct costs. It answers: "How much does the company keep before operating costs?"

Profit Margin: The key to measuring true business profitability

-487.99%

Diluted EPS (TTM)

Explainer

Diluted EPS (TTM) shows the profit per share over the last 12 months. It answers: "How profitable is each share I buy?"

Earnings per Share (EPS): The Key Metric That Beats Headline Profits

-6.54

Return on Equity (TTM)

119.00%

Revenue (TTM)

88.04M

Is it growing?

Revenue Growth (MRQ)

4.90%

Earnings Growth (YOY)

4.89%

Is it risky?

Beta

0.48

Debt to Equity (MRQ)

-2.18

Current Ratio (MRQ)

4.53

Total Debt (MRQ)

1.44B

Who owns it?

Institutional Ownership

115.43%

Insider Ownership

1.13%

Short Interest

16.44%

Shares Outstanding

122.94M

Shares Float

122.30M

Does it pay?

Forward Dividend Yield

0.00%

Payout Ratio

0.00%

Ex. Dividend Date

Dividend Date

How much cash?

Total Cash (MRQ)

882.22M

Operating Cash Flow (TTM)

-510.01M

Levered Free Cash Flow (TTM)

-379.62M

Total Cash per Share (MRQ)

7.16

Cytokinetics, Incorporated

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Indicators

Indicators

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Cytokinetics, Incorporated

Stock Details

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers

Indicators

Indicators

Stock Details

Is it expensive?

Is it profitable?

Is it growing?

Is it risky?

Who owns it?

Does it pay?

How much cash?

52-Week Range Position (52WRP)

Multi-Timeframe Analysis (MTA)

Rate of Change (ROC)

Relative Volume (RVOL)

Exchange Identifiers